2026-04-14T03:25:17Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2203602025-12-05T04:20:28Zcom_2072_1057col_2072_478809col_2072_478917

Hepatocellular carcinoma: what are the differential costs compared to the general population? Darbà, Josep Ascanio, Meritxell Hepatologia Control de costos Carcinogènesi Economia de la salut Política sanitària Hepatology Cost control Carcinogenesis Medical economics Medical policy Hepatocellular carcinoma (HCC), which accounts for about 90% of all primary liver can-cer cases, is the fifth most common malignancy and the second leading cause of cancer-related mor-tality worldwide. This study aims to analyse the differential costs of HCC-related hospital admissionscompared to the general population in Spain (...) 2025-04-09T08:15:53Z 2025-04-09T08:15:53Z 2025-04-01 2025-04-09T08:15:53Z info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion 1369-6998 https://hdl.handle.net/2445/220360 757959 eng Reproducció del document publicat a: https://doi.org/https://doi.org/10.1080/13696998.2025.2484073 Journal of Medical Economics, 2025, vol. 28, num.1, p. 471-478 https://doi.org/https://doi.org/10.1080/13696998.2025.2484073 (c) Taylor & Francis, 2025 http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess 8 p. application/pdf Taylor & Francis Articles publicats en revistes (Economia)